7 Antithrombotic Therapy and Bleeding Risk
Learn how antithrombotic medicines differ, what to monitor, how to recognize bleeding or thrombosis, and how to respond safely to serious bleeding.
How antithrombotic medicines work
Antithrombotic medicines reduce harmful clot formation but can cause bleeding. interfere with clotting factors and are used especially to prevent or treat venous clots and emboli. reduce platelet activation or aggregation and are used especially to prevent arterial events such as myocardial infarction or ischemic stroke.
Either type of therapy may be prescribed alone or in combination. Combining agents generally increases bleeding risk.
Medicine groups and monitoring
Monitoring must match the specific medicine and indication. Confirm the prescribed dose, route, timing, indication, last dose, renal function when relevant, and required laboratory results.
are high-alert medicines. Follow institutional protocols, use required independent checks, and clarify unexpectedly high or low results before administration. Review prescription, over-the-counter, and herbal products; NSAIDs and additional antithrombotic medicines may increase bleeding risk.
Drug groups and monitoring
: Intravenous or subcutaneous heparin enhances antithrombin activity against clotting factors. For therapeutic intravenous therapy, monitor aPTT or heparin anti-Xa according to protocol, as well as platelet count and hemoglobin/hematocrit.
Low-molecular-weight heparin (LMWH): Enoxaparin enhances antithrombin activity, particularly against factor Xa. Monitor CBC, renal function, and clinical bleeding; anti-Xa testing is reserved for selected situations according to protocol.
Vitamin K antagonist: reduces production of vitamin K-dependent clotting factors. Monitor PT/INR; testing frequency depends on stability, dose changes, illness, diet, and interacting medicines.
: Apixaban, rivaroxaban, and edoxaban inhibit factor Xa; dabigatran directly inhibits thrombin. Monitor CBC and renal function periodically and as clinically indicated. Routine INR does not reliably measure their anticoagulant effect.
: Aspirin, clopidogrel, prasugrel, and ticagrelor inhibit platelet activation or aggregation. Assess clinically for bleeding and obtain CBC when indicated; routine INR or aPTT does not measure platelet inhibition.
Recognizing bleeding and thrombosis
Establish a baseline and reassess for changes. Ask about recent bleeding, falls or trauma, procedures, medication adherence, and new medicines. Assess skin and mucosa, urine and stool, injection sites, wounds, vital signs, mental status, and symptoms of anemia or blood loss. Review CBC, platelet count, renal function, and medicine-specific coagulation tests as ordered.
Possible bleeding includes prolonged bleeding from a wound; frequent or extensive bruising; petechiae; recurrent nose or gum bleeding; blood in urine; black or bloody stool; vomiting blood; unusually heavy menstrual bleeding; severe headache; confusion; weakness; dizziness; fainting; or unexplained hypotension or tachycardia. Bleeding into a critical site, such as the brain, spinal canal, or retroperitoneum, or bleeding with hemodynamic instability requires emergency escalation.
Possible thrombosis includes new unilateral leg pain or swelling, sudden shortness of breath or chest pain, coughing blood, or acute facial droop, weakness, speech difficulty, or vision change. Treat these as urgent findings.
A falling platelet count during heparin exposure, particularly with new thrombosis, raises concern for . HIT is prothrombotic despite thrombocytopenia. Promptly notify the prescriber and follow the suspected-HIT protocol, which generally includes stopping heparin and starting a non-heparin anticoagulant when indicated.
decisions and approaches
is a clinician-directed decision based on bleeding severity, the medicine and last dose, renal function, laboratory findings, and thrombosis risk. Initial steps often include holding the suspected medicine, identifying and controlling the bleeding source, providing supportive care, and obtaining urgent consultation. A agent is generally reserved for life-threatening, critical-site, or otherwise uncontrolled major bleeding—not routine minor bruising. itself can increase clotting risk.
Common approaches for severe bleeding
: Four-factor prothrombin complex concentrate (4F-PCC) plus intravenous vitamin K; plasma may be used if PCC is unavailable. Follow local protocol.
UFH: Stop the infusion; protamine may be given under an order or protocol.
LMWH: Stop the medicine; protamine can partially reverse its effect.
Dabigatran: Idarucizumab is a specific agent for life-threatening or uncontrolled bleeding or urgent procedures.
Oral factor Xa inhibitors: Andexanet alfa was historically used for apixaban or rivaroxaban . The FDA approved 2026 labeling revisions removing references to it following its withdrawal from the U.S. market. For serious bleeding, follow current institutional guidance; the treating team may consider 4F-PCC.
: There is no routine specific antidote. Hold therapy when directed and manage the bleeding source; decisions about platelet transfusion or other hemostatic treatment require clinician and specialist judgment.
A normal PT/INR or aPTT does not exclude clinically important DOAC activity. If testing is needed, a drug-specific assay may be appropriate if available; interpretation depends on the medicine and timing. recommendations and product availability can change, so verify current local protocols and consult pharmacy, hematology, or the relevant specialist.
Nursing priorities during excessive bleeding
For suspected major or critical-site bleeding, activate the emergency response or notify the responsible clinician immediately. Stay with an unstable patient and follow emergency protocols.
Assess and support. Check airway, breathing, circulation, vital signs, mental status, pain, perfusion, and visible bleeding. Apply firm direct pressure to accessible external bleeding when appropriate. Prepare for intravenous access, fluids, blood products, imaging, or procedures as ordered.
Clarify drug exposure. Identify the exact antithrombotic, dose, route, indication, and time of last dose. Report other medicines that affect hemostasis and relevant kidney or liver impairment.
Obtain and trend ordered tests. Common assessments include CBC with platelet count, hemoglobin/hematocrit, renal function, type and screen/crossmatch, and drug-appropriate coagulation tests. Do not delay emergency stabilization to obtain routine tests.
Hold and reverse only as directed. With serious bleeding, expect the prescriber to consider withholding therapy and ordering . Administer agents and blood products using the prescribed protocol; monitor for infusion reactions, response, and new thrombosis.
Document and reassess. Record the assessment, bleeding progression, interventions, communication, medication details, laboratory trends, and patient response. Reassess frequently and communicate deterioration immediately.
For minor bleeding, promptly notify the prescriber according to severity and local policy. Do not independently stop long-term antithrombotic therapy without direction unless an emergency protocol applies; interruption may expose the patient to stroke, recurrent venous thromboembolism, or other serious clotting events. Once bleeding is controlled, the treating team should determine whether and when therapy should resume.
Patient teaching and prevention
Teach patients to take the medicine exactly as prescribed. They should not double missed doses or stop treatment without consulting their clinician. Encourage them to carry an up-to-date medication list and tell healthcare professionals, dentists, and pharmacists about their antithrombotic therapy before procedures or starting new medicines.
Review signs that require emergency care, including head injury, severe headache, fainting, uncontrolled bleeding, blood in vomit or stool, chest pain, sudden shortness of breath, or stroke symptoms. Patients taking should keep INR appointments and follow individualized guidance about diet and interactions. Discuss bleeding precautions appropriate to the patient, such as a soft toothbrush and electric razor, and safe pain-relief choices with a clinician or pharmacist.